Endpoints News
Report says AZ-BMS talks are off Read in browser
Endpoints News
Thank you for reading, dupa dupackia!
basic
UPGRADE
M T Wed Th F
5 August, 2026
presented by THE AMERICAN BIOSECURITY INITIATIVE
Why Amer­i­ca's med­i­cine be­came a na­tion­al se­cu­ri­ty ques­tion
top stories
1. Merger talks between AstraZeneca, Bristol Myers are off — report
2. Expedition gets another $115M for its twist on China NewCo model
3. Fujifilm’s Lars Petersen exits, hands leadership baton to COO Maja Pedersen
4.
news briefing
Arrowhead buys PRV for $215M; Twist hopes to raise $300M in public offering
5. Novo Nordisk eyes bolt-on deals as pipeline disappointments pile up
6. Lilly beats forecasts again as tirzepatide makes up nearly two-thirds of revenue
7. Attovia extends biotech IPO streak with $289M listing for three I&I drugs
8. Amgen culls early-stage obesity candidate, makes pipeline updates
9. Gilead’s Yeztugo beats forecasts as HIV PrEP franchise exceeds $1B
10. Merck plans a sac-TMT combo trial with Keytruda as patent cliff looms
11. Pfizer has already made its biggest deals, Bourla says
more stories
• 
in focus
Karen Weintraub
.

For a while it seemed like a real — though confounding — possibility that AstraZeneca might merge with Bristol Myers Squibb. Now, it seems like whatever courtship there was between the two giants is over, and as Max Gelman reports, Wall Street doesn’t seem unhappy.
.
Karen Weintraub
Deputy Editor, Endpoints News
1
by Max Gelman

So much for that.

As­traZeneca and Bris­tol My­ers Squibb are no longer in dis­cus­sions on a merg­er and will not strike a deal, Reuters re­port­ed...

Read the full story
Yi Larson, Expedition Therapeutics CEO
2
by Kyle LaHucik

A US biotech with a slight­ly dif­fer­ent ap­proach to the bur­geon­ing New­Co mod­el has raised an­oth­er $115 mil­lion for its Chi­na-sourced COPD drug can­di­date.

Vir­tu­al...

Read the full story
Endpoints webinars
Aug 19
1:00 pm ET
From pilots to production: AI across R&D, safety, regulatory, and clinical
IBM
Aug 27
12:00 pm ET
Same molecule, different paths: Where value goes in cross-border dealmaking in a new era
PharmCube
Sep 03
11:00 am ET
How leading pharma organizations are putting AI agents to work
Medable
Fujifilm Biotechnologies president Maja Pedersen (L) and strategy advisor Lars Petersen
3
by Anna Brown

Lars Pe­tersen has stepped down from his role as CEO and pres­i­dent at Fu­ji­film Biotech­nolo­gies ef­fec­tive im­me­di­ate­ly, with Chief Op­er­at­ing Of­fi­cer Ma­ja Ped­er­sen tak­ing the...

Read the full story